Drug Addiction - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Drug Addiction - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Drug Addiction - Pipeline Review, H1 2015', provides an overview of the Drug Addiction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Drug Addiction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Drug Addiction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Drug Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Drug Addiction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Drug Addiction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Drug Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Drug Addiction Overview 9
Therapeutics Development 10
Pipeline Products for Drug Addiction - Overview 10
Pipeline Products for Drug Addiction - Comparative Analysis 11
Drug Addiction - Therapeutics under Development by Companies 12
Drug Addiction - Therapeutics under Investigation by Universities/Institutes 13
Drug Addiction - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Drug Addiction - Products under Development by Companies 17
Drug Addiction - Products under Investigation by Universities/Institutes 18
Drug Addiction - Companies Involved in Therapeutics Development 19
Addex Therapeutics Ltd 19
Aphios Corporation 20
Curemark, LLC 21
Embera NeuroTherapeutics, Inc. 22
Gilead Sciences, Inc. 23
Immunovaccine, Inc. 24
Kyorin Pharmaceutical Co., Ltd. 25
Lightlake Therapeutics Inc. 26
Omeros Corporation 27
Rottapharm SpA 28
Teva Pharmaceutical Industries Limited 29
Drug Addiction - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
(oxazepam + metyrapone) - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ADX-71441 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ADX-88178 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
cannabidiol - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CM-1212 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CR-5542 Series - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
dronabinol - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Drug for Dependence - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GS-6637 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ibudilast - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
LT-22 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
MC-100093 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Methoxycoronaridine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
OMS-527 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecule for Drug Addiction - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecule to Inhibit BRD for Cocaine Dependence - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecule to Inhibit Kappa Opioid Receptor for CNS - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecules to Modulate 5HT2 for CNS and Metabolic Disorders - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
TV-1380 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Vaccine for Cocaine Addiction - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Vaccine for Cocaine Addiction - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Vaccine for Methamphetamine Addiction - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Drug Addiction - Recent Pipeline Updates 69
Drug Addiction - Dormant Projects 78
Drug Addiction - Discontinued Products 80
Drug Addiction - Product Development Milestones 81
Featured News & Press Releases 81
Apr 10, 2015: HRA Pharma Closes Investment in Embera NeuroTherapeutics to Advance Development of Novel Therapies for Addiction 81
Sep 23, 2014: Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 81
Aug 09, 2013: Curemark wins patent for CM-1212 to treat drug, alcohol addiction 82
Jun 18, 2013: MediciNova Announces Presentation Of Preliminary Results >From Phase Ib Study Of MN-166 In Methamphetamine Addiction At 75th Annual Meeting Of CPDD 82
Feb 25, 2013: MediciNova's MN-166 Receives Fast Track Designation From FDA For Treatment Of Methamphetamine Dependence 83
Jan 18, 2013: Research team including Dr Gianluca Baio funded by the MRC 84
Jan 03, 2013: MediciNova Provides Development Update On MN-166 85
Sep 04, 2012: NIH Funds UCLA Phase II Study Of MediciNova's MN-166 For Treament Of Methamphetamine Addiction 85
Jan 04, 2011: Scripps Research and Cornell Scientists Create Novel Vaccine that Produces Strong Immunity Against Cocaine High 87
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90

List of Tables

Number of Products under Development for Drug Addiction, H1 2015 10
Number of Products under Development for Drug Addiction - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Comparative Analysis by Unknown Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Drug Addiction - Pipeline by Addex Therapeutics Ltd, H1 2015 19
Drug Addiction - Pipeline by Aphios Corporation, H1 2015 20
Drug Addiction - Pipeline by Curemark, LLC, H1 2015 21
Drug Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H1 2015 22
Drug Addiction - Pipeline by Gilead Sciences, Inc., H1 2015 23
Drug Addiction - Pipeline by Immunovaccine, Inc., H1 2015 24
Drug Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 25
Drug Addiction - Pipeline by Lightlake Therapeutics Inc., H1 2015 26
Drug Addiction - Pipeline by Omeros Corporation, H1 2015 27
Drug Addiction - Pipeline by Rottapharm SpA, H1 2015 28
Drug Addiction - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 29
Assessment by Monotherapy Products, H1 2015 30
Assessment by Combination Products, H1 2015 31
Number of Products by Stage and Target, H1 2015 33
Number of Products by Stage and Mechanism of Action, H1 2015 35
Number of Products by Stage and Route of Administration, H1 2015 37
Number of Products by Stage and Molecule Type, H1 2015 39
Drug Addiction Therapeutics - Recent Pipeline Updates, H1 2015 69
Drug Addiction - Dormant Projects, H1 2015 78
Drug Addiction - Dormant Projects (Contd..1), H1 2015 79
Drug Addiction - Discontinued Products, H1 2015 80